Review
References
|
Adams J, Carder PJ, Downey S, Forbes MA, MacLennan K, Allgar V, Kaufman S, Hallam S, Bicknell R, Walker JJ, Cairnduff F, Selby PJ, Perren TJ, Lansdown M, Banks RE (2000). Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen. Cancer Res. 60:2898-2905. Pubmed |
||||
| Ahmad M, Mahmood Q, Gulzar K, Akhtar MS, Saleem M, Qadir MI (2012). Anti-hyperlipidaemic and hepatoprotective activity of Dodonaea viscosa leaves extracts in alloxan-induced diabetic rabbits (Oryctolagus cuniculus). Pak. Vet. J. 32:50-54. | ||||
|
Ali M, Qadir MI, Saleem M, Janbaz KH, Gul H, Hussain L, Ahmad B (2013). Hepatoprotective potential of Convolvulus arvensis against paracetamol-induced hepatotoxicity. Bangladesh J. Pharmacol. 8:300-304. Crossref |
||||
|
Ameen S, Qadir MI, Ahmad B (2012). Pharmacogenomic approaches in the treatment of breast cancer by tamoxifen. Pak. J. Pharm. Sci. 25:469-476. Pubmed |
||||
| Amin N, Qadir MI, Khan TJ, Abbas G, Ahmad B, Janbaz KH, Ali M (2012). Antibacterial activity of Vacuum liquid chromatography (VLC) isolated fractions of chloroform extracts of seeds of Achyranthes aspera. J. Chem. Soc. Pak. 34:589-592. | ||||
| Asif MA, Qadir MI (2011). Molecular approaches for development of malarial vaccines. Rev. Pharmacol. 4:276-278. | ||||
|
Benoy I, Salgado R, Colpaert C, Weytjens R, Vermeulen PB, Dirix LY (2002). Serum interleukin 6, plasma VEGF, serum VEGF, and VEGF platelet load in breast cancer patients. Clin. Breast Cancer 2:311-315. Crossref |
||||
|
Berezov TT, Ovchinnikova LK, Kuznetsova OM, Karabekova ZK, Vorotnikov IK, Tuleuova AA, Katunina AI, Dvorova EK (2009). Vascular endothelial growth factor in the serum of breast cancer patients. Bull. Exp. Biol. Med. 148:419-424. Crossref |
||||
|
Berns EM, Klijn JG, Look MP, Grebenchtchikov N, Vossen R, Peters H, Geurts-Moespot A, Portengen H, van Staveren IL, Meijer-van Gelder ME, Biker B, Sweep FC, Foekens JA (2003). Combined vascular endothelial growth factor and TP53 status predicts poor response to tamoxifen therapy in estrogen receptor-positive advanced breast cancer. Clin. Cancer Res. 9:1253-1258. Pubmed |
||||
|
Boss EA, Massuger LF, Thomas CM, Geurts-Moespot A, Boonstra H, Sweep CG (2001). Vascular endothelial growth factor in ovarian cyst fluid. Cancer 91:371-377. Crossref |
||||
|
Colleoni M, Rocca A, Sandri MT, Zorzino L, Masci G, Nolè F, Peruzzotti G, Robertson C, Orlando L, Cinieri S, de BF, Viale G, Goldhirsch A (2002). Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann. Oncol. 13:73-80 Crossref |
||||
|
Cooper BC, Ritchie JM, Broghammer CL, Coffin J, Sorosky JI, Buller RE, Hendrix MJ, Sood AK (2002). Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer. Clin. Cancer Res. 8:3193-3197. Pubmed |
||||
|
Coskun U, Günel N, Toruner FB, Sancak B, Onuk E, Bayram O, Cengiz O, Yilmaz E, Elbeg S, Ozkan S (2003). Serum leptin, prolactin and vascular endothelial growth factor (VEGF) levels in patients with breast cancer. Neoplasma 50:41-46. Pubmed |
||||
|
Cubo T, Padilla D, de la Osa G, Palomino T, García M, Pardo R, Martín J, Arévalo E, Hernández J (2004). Serum vascular endothelial growth factor levels in patients with colorectal cancer and its prognostic significance. Med. Clin. 122:201-204. Crossref |
||||
|
Demirkiran F, Kumbak B, Bese T, Arvas M, Benian A, Aydin S, Uzun H, Sanioglu C, Aydinli K, Kösebay D (2003). Vascular endothelial growth factor in adnexal masses. Int. J. Gynaecol. Obstet. 83:53-58. Crossref |
||||
|
Dunst J, Becker A, Lautenschläger C, Markau S, Becker H, Fischer K, Haensgen G (2002). Anemia and elevated systemic levels of vascular endothelial growth factor (VEGF). Strahlenther Onkol. 78(8):436-441. Crossref |
||||
|
Dunst J, Pigorsch S, Hansen G, Hintner I, Lautenschläger C, Becker A (1999). Low hemoglobin is associated with increased serum levels of vascular endothelial growth factor (VEGF) in cancer patients. Strahlenther Onkol. 175:93-96 Crossref |
||||
| Ehsan O, Qadir MI, Malik SA, Abbassi WS and Ahmad B (2012). Efficacy of nanogold-insulin as a hypoglycemic agent. J. Chem. Soc. Pak. 34:365-370. | ||||
|
Eisma RJ, Spiro JD, Kreutzer DL (1997). Vascular endothelial growth factor expression in head and neck squamous cell carcinoma. Am. J. Surg. 174:513-517. Crossref |
||||
| Foekens JA, Peters HA, Grebenchtchikov N, Look MP, Meijer-van Gelder ME, Geurts-Moespot A, van der Kwast TH, Sweep CG, Klijn JG (2001). High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer 61:5407-5414. | ||||
|
Gasparini G, Toi M, Gion M, Verderio P, Dittadi R, Hanatani M, Matsubara I, Vinante O, Bonoldi E, Boracchi P, Gatti C, Suzuki H, Tominaga T (1997). Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J. Natl. Cancer Inst. 89:139-147. Crossref |
||||
|
Graeven U, Andre N, Achilles E, Zornig C, Schmiegel W (1999). Serum levels of vascular endothelial growth factor and basic fibroblast growth factor in patients with soft-tissue sarcoma. J. Cancer Res. Clin. Oncol. 125:577-581. Crossref |
||||
|
Granato AM, Nanni O, Falcini F, Folli S, Mosconi G, De Paola F, Medri L, Amadori D, Volpi A (2004). Basic fibroblast growth factor and vascular endothelial growth factor serum levels in breast cancer patients and healthy women: useful as diagnostic tools? Breast Cancer Res. 6:R38-45. Crossref |
||||
|
Hazelton D, Nicosia RF, Nicosia SV (1999). Vascular endothelial growth factor levels in ovarian cyst fluid correlate with malignancy. Clin. Cancer Res. 5:823-829. Pubmed |
||||
|
Heer K, Kumar H, Read JR, Fox JN, Monson JR, Kerin MJ (2001). Serum vascular endothelial growth factor in breast cancer: its relation with cancer type and estrogen receptor status. Clin. Cancer Res. 7:3491-3494. Pubmed |
||||
| Hussain A, Khalid SH, Qadir MI, Massud A, Ali M, Khan IU, Saleem M, Iqbal MS, Asghar S, Gul H (2011). Water Uptake and Drug Release Behaviour of Methyl Methacrylate-co-itaconic acid [P(MMA/IA)] Hydrogels Cross-linked with Methylene Bis-acrylamide. J. Drug Deliv. Sci. Tech. 21:249-255. | ||||
|
Hyodo I, Doi T, Endo H, Hosokawa Y, Nishikawa Y, Tanimizu M, Jinno K, Kotani Y (1998). Clinical significance of plasma vascular endothelial growth factor in gastrointestinal cancer. Eur. J. Cancer 34:2041-2045. Crossref |
||||
| Janbaz KH, Jan A, Qadir MI, Gilani AH (2013a). Spasmolytic, bronchodilator and vasorelaxant activity of methanolic extract of Tephrosia purpurea. Acta. Pol. Pharm. 79:261-269. | ||||
|
Janbaz KH, Nizsar U, Ashraf M and Qadir MI (2012). Spasmolytic, bronchodilator and antioxidant activities of Erythrina superosa Roxb. Acta. Pol. Pharm. 69:1111-1117. Pubmed |
||||
|
Janbaz KH, Qadir MI, Ahmad B, Sarwar A, Yaqoob N, Masood MI (2012). Tuberculosis – Burning Issues: Multi-Drug Resistance and HIV-Coinfection. Critical Rev. Micro. 38:267–275. Crossref |
||||
| Janbaz KH, Qadir MI, Jan A, Gilani AH (2013b). Anti-diarrheal activity of methanolic extract of Tephrosia purpurea. Acta. Pol. Pharm. 79:345-347. | ||||
|
Javed F, Qadir MI, Janbaz KH, Ali M (2011). Novel drugs from marine microorganisms. Crit. Rev. Micro. 37:245-249. Crossref |
||||
|
Karayiannakis AJ, Syrigos KN, Zbar A, Baibas N, Polychronidis A, Simopoulos C, Karatzas G (2002). Clinical significance of preoperative serum vascular endothelial growth factor levels in patients with colorectal cancer and the effect of tumor surgery. Surgery 131:548-555. Crossref |
||||
| Khalid SH, Qadir MI, Massud A, Ali M, Rasool MH (2009). Effect of degree of cross-linking on swelling and drug release behaviour of poly (methyl methacrylate-co-itaconic acid) [P(MMA/IA)] hydrogels for site specific drug delivery. J. Drug Deliv. Sci. Tech. 19:413-418. | ||||
|
Kim BC, Han SI, Lim SC (2009). Interpretation of Pin-1 and VEGF-C expression in breast infiltrating duct carcinoma. Oncol. Rep. 22:1381-1390. Pubmed |
||||
|
Kraft A, Weindel K, Ochs A, Marth C, Zmija J, Schumacher P, Unger C, Marmé D, Gastl G (1999). Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer 85:178-187 Crossref |
||||
|
Linderholm BK, Hellborg H, Johansson U, Elmberger G, Skoog L, Lehtiö J, Lewensohn R (2009). Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer. Ann. Oncol. 20:1639-1646 Crossref |
||||
|
Lissoni P, Malugani F, Bonfanti A, Bucovec R, Secondino S, Brivio F, Ferrari-Bravo A, Ferrante R, Vigoré L, Rovelli F, Mandalà M,Viviani S, Fumagalli L, Gardani GS (2001). Abnormally enhanced blood concentrations of vascular endothelial growth factor (VEGF) in metastatic cancer patients and their relation to circulating dendritic cells, IL-12 and endothelin-1. J. Biol. Regul. Homeost. Agents 15:140-144. Pubmed |
||||
|
Lowery AJ, Sweeney KJ, Molloy AP, Hennessy E, Curran C, Kerin MJ (2008). The effect of menopause and hysterectomy on systemic vascular endothelial growth factor in women undergoing surgery for breast cancer. BMC Cancer 8:279. Crossref |
||||
|
Manders P, Beex LV, Tjan-Heijnen VC, Span PN, Sweep CG (2003). Vascular endothelial growth factor is associated with the efficacy of endocrine therapy in patients with advanced breast carcinoma. Cancer 98:2125-2132. Crossref |
||||
|
Masood MI, Qadir MI, Shirazi JH, Khan IU (2011). Beneficial effects of lactic acid bacteria on human beings. Crit. Rev. Micro. 37:91-98. Crossref |
||||
| Naz S, Qadir MI, Ali M, Janbaz KH (2012). Nanotechnology for imaging and drug delivery in cancer. J. Chem. Soc. Pak. 34:107-111. | ||||
| Nisar L, Qadir MI, Malik SA, Tabassum N (2011). Characterization of the immunodominant regions within gp41 of env gene of HIV in Pakistan. J. Chem. Soc. Pak. 33:545-548. | ||||
|
Oehler MK, Caffier H (2000). Prognostic relevance of serum vascular endothelial growth factor in ovarian cancer. Anticancer Res. 20(6D):5109-5112. Pubmed |
||||
| Qadir MI (2009). Medicinal and cosmetological importance of Aloe vera. Int. J. Nat. Ther. 2:21-26. | ||||
| Qadir MI (2010). Medicinal values of ginger. Int. J. Nat. Ther. 3:19-22. | ||||
|
Qadir MI (2011). Qadirvirtide. Pak. J. Pharm. Sci. 24:593-595. Pubmed |
||||
| Qadir MI, Malik SA (2009). Effect of Eugenia jambolana leaves extracts on blood glucose levels of experimental diabetic rabbits. Pharmacologyonline 3:829-835. | ||||
| Qadir MI, Malik SA (2010). Anti-diabetic activity of inorganic metals Eugenia jambolana Lam. (Myrtaceae) flowers. Pharmacologyonline 2:979-985. | ||||
|
Qadir MI, Malik SA (2011). Genetic variation in the HR region of the env Gene of HIV: A perspective for resistance to HIV fusion inhibitors. AIDS Res. Hum. Retrovir. 27:57-63. Crossref |
||||
|
Quaranta M, Daniele A, Coviello M, Venneri MT, Abbate I, Caringella ME, Di Tardo S, Divella R, Trerotoli P, Di Gennaro M, Schittulli F, Fransvea E, Giannelli G (2007). MMP-2, MMP-9, VEGF and CA 15.3 in breast cancer. Anticancer Res. 27(5B):3593-600. Pubmed |
||||
|
Riedel F, Götte K, Schwalb J, Wirtz H, Bergler W, Hörmann K (2000). Serum levels of vascular endothelial growth factor in patients with head and neck cancer. Eur. Arch. Otorhinolaryngol. 257:332-336. Crossref |
||||
|
Saleem M, Qadir MI, Perveen N, Ahmad B, Saleem U, Irshad T, Ahmad B (2013). Inhibitors of apoptotic proteins: New targets for anti-cancer therapy. Chem. Biol. Drug Desi. 82:243-251. Crossref |
||||
|
Salgado R, Vermeulen PB, Benoy I, Weytjens R, Huget P, Van Marck E, Dirix LY (1999). Platelet number and interleukin-6 correlate with VEGF but not with bFGF serum levels of advanced cancer patients. Br. J. Cancer 80:892-897. Crossref |
||||
|
Salven P, Mänpää H, Orpana A, Alitalo K, Joensuu H (1997). Serum vascular endothelial growth factor is often elevated in disseminated cancer. Clin. Cancer Res. 3(5):647-651 Pubmed |
||||
|
Salven P, Orpana A, Joensuu H (1999a). Leukocytes and platelets of patients with cancer contain high levels of vascular endothelial growth factor. Clin. Cancer Res. 5:487-491. Pubmed |
||||
|
Salven P, Perhoniemi V, Tykkä H, Mäenpää H, Joensuu H (1999b). Serum VEGF levels in women with a benign breast tumor or breast cancer. Breast Cancer Res. Treat. 53:161-166. Crossref |
||||
|
Sato K, Tsuchiya N, Sasaki R, Shimoda N, Satoh S, Ogawa O, Kato T (1999). Increased serum levels of vascular endothelial growth factor in patients with renal cell carcinoma. Jpn. J. Cancer Res. 90:874-879. Crossref |
||||
|
Stockhammer G, Obwegeser A, Kostron H, Schumacher P, Muigg A, Felber S, Maier H, Slavc I, Gunsilius E, Gastl G (2000). Vascular endothelial growth factor (VEGF) is elevated in brain tumor cysts and correlates with tumor progression. Acta Neuropathol. 100:101-105. Crossref |
||||
|
Takano S, Yoshii Y, Kondo S, Suzuki H, Maruno T, Shirai S, Nose T (1996). Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients. Cancer Res. 56:2185-2190. Pubmed |
||||
|
Tuttle RM, Fleisher M, Francis GL, Robbins RJ (2002). Serum vascular endothelial growth factor levels are elevated in metastatic differentiated thyroid cancer but not increased by short-term TSH stimulation. J. Clin. Endocrinol. Metab. 87:1737-1742. Crossref |
||||
|
Verheul HM, Hoekman K, Luykx-de Bakker S, Eekman CA, Folman CC, Broxterman HJ, Pinedo HM (1997). Platelet: transporter of vascular endothelial growth factor. Clin. Cancer Res. 3:2187-2190. Pubmed |
||||
|
Weindel K, Moringlane JR, Marmé D, Weich HA (1994). Detection and quantification of vascular endothelial growth factor/vascular permeability factor in brain tumor tissue and cyst fluid: the key to angiogenesis? Neurosurgery 35:439-448. Crossref |
||||
Copyright © 2024 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0
